Mayo Clinic announced the Clinical Data Analytics Platform as the first venture under the Mayo Clinic Platform, a strategic initiative to improve health care through insights and knowledge derived from data.
The Clinical Data Analytics Platform will apply advanced data analytics on deidentified data from Mayo Clinic and other organizations, as well as the vast information in the scientific literature to advance medicine and improve the health of patients. Clinical Data Analytics Platform is based on a federated architecture, which enables multiple participants to build a common, robust artificial intelligence and machine learning model without sharing datasets, thus addressing critical issues such as data privacy, security and access rights to heterogeneous sources of data.
Mayo Clinic selected n f erence, a Cambridge-based augmented intelligence company, as its first Clinical Data Analytics Platform partner to accelerate drug discovery and development across the biopharmaceutical ecosystem to create cures for patients. It will focus on identifying targets and biomarkers for new drugs, optimal matching of patients with therapeutic regimen, and real world data and evidence applications, such as label expansion, postmarketing surveillance and drug purposing. The nference company will be the exclusive partner for analytic services to the biopharmaceutical industry and will combine its proprietary knowledge synthesis platform with the clinical expertise of Mayo Clinic physicians and scientists.
Platform business models have been a force of disruption in many sectors, and the rapid digitalization of health care is affording us an unprecedented opportunity to solve complex medical problems and improve lives of people on a global scale. John Halamka, M.D., Mayo Clinic Platform president
The explosion of new data regarding the biology of disease has far outpaced the human ability to consume and make sense of it, creating a challenge for scientists working to translate biomedical data into new treatments.
The novel therapeutic agents identified and created through the power of Clinical Data Analytics Platform have transformative potential to expand treatment options for the most serious or complex illnesses. With these new tools, Mayo Clinic will evolve its research capabilities to unlock massive datasets of the biology of disease to find new therapies faster.
For more than a century, our patients have entrusted us with their biomedical information, with the knowledge that Mayo Clinic would use it to advance the science of medicine. Advanced data and technology capabilities offer great potential to not just improve the health of patients through the treatment of disease but to prevent and cure it. Clark Otley, M.D., chief medical officer for the Mayo Clinic Platform
Last year, Mayo Clinic launched the Mayo Clinic Platform, a coordinated portfolio approach to create new platform ventures and leverage emerging technologies, such as artificial intelligence, connected health care devices and natural language processing. The Mayo Clinic Platform is designed to include an ecosystem of partners that will complement Mayo Clinic's clinical capabilities and provide access to scalable solutions.
The creation of an expansive platform of deidentified clinical and molecular data that places patient privacy first, is imperative for leveraging institutional knowledge. Our technology makes the predominantly unstructured biomedical knowledge computable, facilitating the discovery and development of new therapeutics. Murali Aravamudan, co-founder and chief executive officer, n f erence
The n f erence company recently announced the completion of a $60 million Series B round to advance its Augmented Intelligence platform. New investors Mayo Clinic and NTT Venture Capital participated in the financing along with existing investors Matrix Partners and Matrix Capital Management. Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology